Levels of prostaglandin E metabolite, the major urinary metabolite of prostaglandin E2, are increased in smokers
Levels of prostaglandin E metabolite, the major urinary metabolite of prostaglandin E2, are increased in smokers
复制标题
DOI：
10.1158/1078-0432.ccr-05-0733
复制
发表时间：
2005-08-15
影响因子：
11.5
通讯作者：
Duffield-Lillico, AJ
中科院分区：
文献类型：
--
作者：
Gross, ND;Boyle, JO;Duffield-Lillico, AJ
目的：在与烟草相关的上呼吸消化道恶性肿瘤中观察到环氧合酶-2和前列腺素E-2（PGE（2））水平升高。此外，接触烟草烟雾可以刺激PGE的合成（2）。最近的证据表明，尿中PGE代谢物（PGE-M）可作为全身PGE（2）产生的指标。在这项研究中，我们调查了吸烟者和头颈部鳞状细胞癌（HNSCC）患者的尿PGE-M水平是否升高。实验设计：58例HNSCC病例和29例年龄和性别匹配的健康对照者前瞻性地参加了这项研究。从每名参与者中获得详细的吸烟史和单次排尿标本。尿PGE-M的水平进行了量化，在一个盲的方式使用质谱和吸烟史和肿瘤status.Results：调整病例对照matching，中位尿PGE-M水平显着较高的吸烟者（15.7纳克/毫克肌酐）相比，从未吸烟者（9.9纳克/毫克肌酐）为整个研究人群（n = 87，P = 0.005）。在健康对照组中，吸烟者的尿PGE-M浓度（15.2 ng/mg肌酐）几乎是从不吸烟者（7.8 ng/mg肌酐）的两倍（P = 0.001）。在当前吸烟者和既往吸烟者中，以及在包年暴露量更大的人群中，观察到PGE-M水平更高。与健康controls.Conclusions：吸烟者尿PGE-M水平升高，在HNSCC患者中未观察到PGE-M的显着差异。尿PGE-M可作为烟草烟雾暴露影响的非侵入性生物标志物。
Purpose: Increased levels of cyclooxygenase-2 and prostaglandin E-2 (PGE(2)) have been observed in tobacco-related malignancies of the upper aerodigestive tract. Moreover, exposure to tobacco smoke can stimulate the synthesis of PGE(2). Recent evidence suggests that urinary PGE metabolite (PGE-M) can be used as an index of systemic PGE(2) production. In this study, we investigated whether levels of urinary PGE-M were increased in smokers and in patients with head and neck squamous cell carcinoma (HNSCC).Experimental Design: Fifty-eight HNSCC cases and 29 age- and gender-matched healthy controls were prospectively enrolled in the study. A detailed smoking history and single void urine specimen were obtained from each participant. Levels of urinary PGE-M were quantified in a blinded fashion using mass spectrometry and compared with smoking history and tumor status.Results: Adjusted for case-control matching, median urinary PGE-M levels were significantly higher in ever smokers (15.7 ng/mg creatinine) compared with never smokers (9.9 ng/mg creatinine) for the entire study population (n = 87, P = 0.005). Concentrations of urinary PGE-M were nearly doubled in ever smokers (15.2 ng/mg creatinine) versus never smokers (7.8 ng/mg creatinine) among healthy controls (P = 0.001). Higher PGE-M levels were observed in current versus former smokers and in those with greater pack-year exposure. A significant difference in amounts of PGE-M was not observed in patients with HNSCC versus healthy controls.Conclusions: Increased levels of urinary PGE-M were observed in smokers. Urinary PGE-M may have use as a noninvasive biomarker of the effects of tobacco smoke exposure.